Poliovirus therapy for recurrent glioblastoma has three year survival rate of 21 percent: Phase 1 study shows long-term survival benefit for a lethal cancer

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, […]

» Read more
1 2 3